The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...

Dr. Villy Valcheva, CEO of GH Research, expressed optimism about the trial's results, stating, "Today, as we share our unprecedented positive Phase 2b data, we celebrate a significant milestone in our ...

A new clinic in Stratford is offering ketamine treatment to help people with mental health conditions.Ketamine has been used ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

A new psychedelic-assisted therapy clinic has opened in Edmonton and psychologists say the field has shown promising results ...

HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics ...

In the past year, the University of Arkansas for Medical Sciences has added three "groundbreaking" programs in the area of psychiatric treatment, according to Dr. Laura Dunn, director of the ...

The symptoms of mental health disorders and chronic pain affect every facet of life, especially during the dark, cold days of ...